Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

(2011) N. Korde et al.   BLOOD

From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention

(2011) Ola Landgren et al.   CLINICAL CANCER RESEARCH

Diagnosis of Smoldering Multiple Myeloma

(2011) S. Vincent Rajkumar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study

(2010) Martin Hjorth et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

(2009) Ernesto Pérez-Persona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations

(2009) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

(2008) B. Barlogie et al.   BLOOD

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD